Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma

BACKGROUND: Checkpoint inhibitors targeting programmed death receptor-1 (PD-1) have been tested in the neoadjuvant setting for the treatment of locoregionally advanced head and neck squamous cell carcinoma (HNSCC); however, response rates are modest. We hypothesized that adding stereotactic body rad...

Descripción completa

Detalles Bibliográficos
Autores principales: Leidner, Rom, Crittenden, Marka, Young, Kristina, Xiao, Hong, Wu, Yaping, Couey, Marcus A, Patel, Ashish A, Cheng, Allen C, Watters, Amber L, Bifulco, Carlo, Morris, George, Rushforth, Lessli, Nemeth, Shorin, Urba, Walter J, Gough, Michael, Bell, R Bryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108690/
https://www.ncbi.nlm.nih.gov/pubmed/33963014
http://dx.doi.org/10.1136/jitc-2021-002485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108690/
https://www.ncbi.nlm.nih.gov/pubmed/33963014
http://dx.doi.org/10.1136/jitc-2021-002485

Ejemplares similares